Clinical trial
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial…
NCT00086892 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00086892 |
|---|---|
| Title | Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation of Cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240) in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, carboplatin |
| Start date | Jun 1, 2004 |
| Primary completion | Apr 1, 2006 |
| First posted | Jul 12, 2004 |
| Last update posted | Feb 14, 2014 |
| Countries | Australia, Canada, Japan, Norway, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: